Literature DB >> 6302318

Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus.

C M Edson, D A Thorley-Lawson.   

Abstract

In pulse-chase experiments, the three major Epstein-Barr virus envelope glycoproteins, gp350/300, gp250/200, and gp85, were shown to be synthesized from separate precursors of 190,000, 160,000, and 83,000 daltons, respectively. These three pulse-labeled species were chased into the mature forms of the glycoproteins between 1 and 3 h after transfer to nonradioactive medium. Digestion of precursor forms with endo-beta-N-acetylglucosaminidase H (endo H) yielded polypeptides of 160,000, 120,000, and 75,000 daltons. Comparison of these results with those from experiments with tunicamycin, which specifically blocks N-linked glycosylation, indicated that some other post-translational modification(s), probably O-linked glycosylation, contributes about 100,000 and 60,000 daltons of apparent molecular mass to gp350/300 and gp250/200, respectively. Experiments with endo H showed that mature gp350/300 and gp250/200 contain complex-type (endo H-resistant) N-linked glycosyl chains, whereas gp85 contains both high-mannose (endo H-sensitive)- and complex-type oligosaccharides. In contrast to the results obtained with the three envelope glycoproteins, no precursor forms of the two unglycosylated protein, p160 (the major Epstein-Barr virus capsid antigen) and p140 (an envelope protein), were detected. The partial proteolytic maps of gp350/300 and gp250/200 were quite similar, suggesting that polypeptide sequence homology could account for at least part of the observed serological cross-reactivity of the two proteins. Taken together, these results demonstrate that the polypeptide portions of gp350/300 and gp250/200 are closely related but not derived from a common precursor. Furthermore, the polypeptide portions comprise half or less of the apparent molecular weight of the mature glycoproteins on sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302318      PMCID: PMC255157     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Analysis of early and late Epstein-Barr virus associated polypeptides by immunoprecipitation.

Authors:  N Mueller-Lantzsch; N Yamamoto; H zur Hausen
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas.

Authors:  D H Crawford; M A Epstein; G W Bornkamm; B G Achong; S Finerty; J L Thompson
Journal:  Int J Cancer       Date:  1979-09-15       Impact factor: 7.396

3.  Localization of two cellular forms of the vesicular stomatitis viral glycoprotein.

Authors:  D M Knipe; H F Lodish; D Baltimore
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

4.  Proposal for a common oligosaccharide intermediate in the synthesis of membrane glycoproteins.

Authors:  P W Robbins; S C Hubbard; S J Turco; D F Wirth
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

5.  Processing of high mannose oligosaccharides to form complex type oligosaccharides on the newly synthesized polypeptides of the vesicular stomatitis virus G protein and the IgG heavy chain.

Authors:  I Tabas; S Schlesinger; S Kornfeld
Journal:  J Biol Chem       Date:  1978-02-10       Impact factor: 5.157

6.  Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

Authors:  D A Thorley-Lawson
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

7.  Tumor initiators and promoters in the induction of Epstein-Barr virus.

Authors:  H zur Hausen; G W Bornkamm; R Schmidt; E Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

8.  Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.

Authors:  D W Cleveland; S G Fischer; M W Kirschner; U K Laemmli
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

9.  Polypeptides of the Epstein-Barr virus membrane antigen complex.

Authors:  D A Thorley-Lawson; C M Edson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

10.  Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells.

Authors:  L F Qualtiere; G R Pearson
Journal:  Int J Cancer       Date:  1979-06-15       Impact factor: 7.396

View more
  20 in total

1.  Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells.

Authors:  M R Torrisi; M Cirone; A Pavan; C Zompetta; G Barile; L Frati; A Faggioni
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

3.  DNA sequence of the herpes simplex virus type 1 gene encoding glycoprotein gH, and identification of homologues in the genomes of varicella-zoster virus and Epstein-Barr virus.

Authors:  D J McGeoch; A J Davison
Journal:  Nucleic Acids Res       Date:  1986-05-27       Impact factor: 16.971

4.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Characterization of herpesvirus sylvilagus glycoproteins released into the culture medium of infected cells: antisera to gp13 and gp32 neutralize viral infectivity in vitro and identify antigens on plasma membranes of infected cells.

Authors:  A K Patick; H C Hinze
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

7.  Identification of the Epstein-Barr virus gp85 gene.

Authors:  T Heineman; M Gong; J Sample; E Kieff
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

8.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200).

Authors:  M Hummel; D Thorley-Lawson; E Kieff
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

10.  Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.

Authors:  Barry R O'Keefe; Donald F Smee; Jim A Turpin; Carrie J Saucedo; Kirk R Gustafson; Toshiyuki Mori; Dennis Blakeslee; Robert Buckheit; Michael R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.